Hinge Health Grew 52% and Still Told Investors to Expect Flat Pricing Through 2027

The saplings are lovely. The tree is still MSK.

Hinge Health's Q3 2026 was, on its face, a quarter with nothing to apologise for. Revenue of $235 million, up 52%. Gross margin of 88%, up roughly 480 basis points. Operating income of $77 million — a 33% operating margin, up about 1,300 basis points year-over-year. Free cash flow of $120 million, a 51% margin. Last-twelve-month calculated billings of $960 million, up 54%. Guidance raised to $879–881 million of revenue (50% growth at the midpoint) and $266–268 million of operating income.

The tape had already voted. Shares are up 207% since the May 2025 IPO, a path that included a brutal 30-week, 31% drawdown before a 139% run over twelve weeks and a further 46% over the last ninety days. Nothing in this print broke that.

Q3 was another strong proof point that automated care delivery works for our members, our clients, our partners, and our financials.

But the interesting thing in this call is not the beat. It is the rotation in what management chose to foreground — and the arithmetic they quietly conceded on the way through.

From GI hype cycle back to the cash cow

Look at the company's own keyword history. Two quarters ago the top theme was migraine care. Last quarter it was GI care and Cylinder Health, with digestive health and a whole vocabulary of unmet need. This quarter, the number one keyword is core MSK — by a wide margin — and it is one of the biggest gainers in the name's momentum history.

That is not an accident of language. Dan Perez spent the product section of the prepared remarks walking through Movement Analysis and a redesigned exercise experience, then said the quiet part loudly:

Then came the timing reset. The integrated GI program is targeted for summer 2027. The 9 million lives and 800-plus clients on Migraine launch through Q1 2027. And revenue from either, in the CEO's words, is expected to arrive in 2028, "once we've had a full 2027 selling season with the integrated program." For a company whose last two calls sold the adjacency story hard, planting a flag on the old business is a meaningful tell.

The one number that actually moves the model

Because pricing is frozen. Full-year yield guidance went to 4.6% from 4.45%, and CFO James Budge was unambiguous about average selling price:

Gross margin is likewise capped — management said it will again target 85% next year rather than push higher, choosing to reinvest in member experience and care-team headcount. Which leaves exactly two growth pistons: eligible lives (~25.5 million LTM average) and yield. Everything else is operating leverage.

And the yield engine is real, but its composition has shifted. Targeted, claims-driven enrollment campaigns are up almost 75% year over year, while member renewals are up almost 25%. That is a retention story more than a conquest story — and the keyword tape agrees. renewal is one of this quarter's biggest gainers, while Win rates and New clients appear in the name's decliner list even as executives talked them up on the call. The emphasis has quietly moved from winning logos to squeezing more out of the ones already signed.

Worth a sanity check against the filing history: trailing revenue of $213M as of the July quarter, +53% yoy, gross margin of 86.4%, and free cash flow up +114% year-over-year. The numbers support the story management is telling. They just don't support a story where price or mix does any of the work.

The succession, and what the moat is not

The loudest single keyword in this quarter's package isn't a product at all: it's Aaryn Pure, newly elevated to run go-to-market as President Jim Pursley steps back at year-end to join the board. The succession was handled warmly and without drama — 100% health plan retention across 60-plus PBM, TPA and plan partners, with Pure noting the company is "always in some kind of cycle of renewals." Continuity, not disruption, is the message.

The other moat claim to test is surgery and HingeSelect. Provider density now stands at roughly 5,500 locations, lives on the product have doubled since the June investor day, and Perez was careful to describe it as a precision network that complements rather than competes with health plans. He also pre-emptively dampened it: "HingeSelect will be a slower burn than a digital program that could be available nationwide on day one."

Note how the prior-quarter swagger has been sanded down. In August, Perez was happy to say of a competitor: “we believe we're about three to four times larger than second place” — Daniel Perez, Co-Founder and CEO · 2026-08-04. This quarter the competitive language is about "dominating the space" and clients switching over, but the sharper edges are gone — and the more sober framing from May still applies: “we are only about 1% of the PT market in America” — Daniel Perez, Co-Founder and CEO · 2026-05-05. That is genuinely a long runway; it is also the reason the growth has to come from penetration, not price.

One thread does tie Hinge to the broader tape. GLP-1 growth sits among the market's better-performing healthcare themes over the last year, and Hinge is now positioning GI care explicitly against the gastrointestinal side effects of that drug class — a demand driver that is external, secular, and not of the company's making. Its engagement-based billing also rhymes with the outcome based pricing language that has been climbing across the market's thirty-day advancers. The company is riding a real wave there.

The verdict

Nothing broke this quarter. Everything accelerated. The reason to pay attention is the guided shape of 2027: flat ASP, gross margin held at 85%, new products contributing nothing until 2028, and the growth algorithm explicitly relying on lives and yield. That is a high-quality machine — it produced a 33% operating margin on 52% growth, and management reiterated a path to 35%+. But it is a machine with no pricing lever, a just-installed commercial chief, and a stock that has already re-rated 207% from its debut. The bet is that the ~88% of US lives without digital MSK keep converting. The saplings can wait.